Mazen Hashisho, MD
Vascular Surgery · Garden Grove, CANPI 1255524427
Payments from drug & device makers
What this record shows
This record is dominated by other: $94,000 of the $99,096 with a category attached, or 94.9%. Angiodynamics, Inc. accounts for 95.2% of it on its own, with 24 other manufacturers making up the rest. 2025 is the largest year on record at $31,502, more than ten times the $118 reported in 2019. Among vascular surgery clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 140 payments — averaging $707.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Angiodynamics, Inc.$94K
- Boston Scientific$1K
- Bard Peripheral Vascular, Inc.$884
- Medtronic$601
- Johnson & Johnson$295
- BD$290
- plus $1K from 19 others
What the payments were for
- Food & beverage$5,0965%
- Other$94,00095%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Angiodynamics, Inc. | 7 | $94,302 |
| Boston Scientific | 34 | $1,443 |
| Bard Peripheral Vascular, Inc. | 20 | $884 |
| Medtronic | 14 | $601 |
| Johnson & Johnson(2 entities) | 13 | $295 |
| BD | 6 | $290 |
| Tactile Systems Technology Inc | 7 | $257 |
| Reflow Medical Inc | 8 | $182 |
| Smith+Nephew | 7 | $172 |
| Bioventus LLC | 1 | $90 |
| Cardiva Medical, Inc. | 3 | $76 |
| Lemaitre Vascular, Inc. | 4 | $73 |
| Baxter Healthcare | 2 | $70 |
| Cordis US CORP. | 2 | $54 |
| Abbott | 2 | $45 |
| Terumo Medical Corporation | 1 | $41 |
| Organogenesis Inc. | 1 | $34 |
| Nevro Corp. | 1 | $32 |
| Mimedx Group, Inc. | 1 | $26 |
| Urgo Medical North America, LLC | 1 | $25 |
| Teleflex LLC | 1 | $24 |
| Stryker | 1 | $24 |
| Merck | 1 | $23 |
| Mozarc Medical US LLC | 1 | $18 |
| Covidien LP | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$99,096 in reported general payments places this provider in the 95th percentile of 519 vascular surgery providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ClopidogrelClopidogrel Bisulfate | 42 | $483 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 20 | $236 |
| Methylprednisolone | 15 | $80 |
Paid to pharmacies, not to this prescriber.
Other vascular surgery in Garden Grove
- Son DuongFountain Valley$503K
- Venita ChandraPalo Alto$488K
- Sukgu HanLos Angeles$477K
- Leigh Ann ObanionFresno$469K
- Trevor DerderianRancho Mirage$359K
- Karthikeshwar KasirajanPalo Alto$349K
- Johnathon RolloLos Angeles$337K
- Melissa LojaFairfield$272K
- Jason LeePalo Alto$228K
- John LaneSan Diego$212K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.